IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-04-02 (fiercebiotech.com)
Through a CRO's perspective: Innovative, Agile Solutions In Vaccine Efficacy Testing |
Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence's release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories' Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. | Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence's release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories' Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic.
Read more
2025-03-04 (globenewswire.com)
SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.
TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating...
Read more
2025-01-13 (stocktitan.net)
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Verastem strengthens financial position with $150M credit facility and strategic IQVIA partnership to support 2025 launch of avutometinib for ovarian cancer treatment.
Read more
2024-05-07 (financialexpress.com)
Dr. Reddy's Q4FY24 Results: Consumer Health segment to drive growth of India Business; To focus on M&A opportunities in FY25 - Healthcare News | The Financial Express
Dr. Reddy's Q4FY24 Results: During the quarter, the company launched three new brands in India, taking the annual total to 13.
Read more
2024-03-27 (livemint.com)
Dr. Reddy’s to promote and distribute Sanofi’s vaccine brands
The tie-up gives DRL a stronger portfolio and takes it to second place among vaccine players in India.
Read more
2023-01-31 (businesswire.com)
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broa
Read more
2022-09-28 (business-standard.com)
IQVIA announces partnership with Dr Reddy's Laboratories for CRM Solution for India Field Force
Mumbai (Maharashtra)/Bangalore (Karnataka) [India], September 28 (ANI/BusinessWire India): IQVIA (NYSE: IQV) today announced that Dr. Reddy's Laboratories (Dr Reddy's), a leading multinational pharmaceutical company based in India, has selected IQVIA Orchestrated Customer Engagement (OCE) platform as its core CRM solution for its entire field force in India.
Read more
2022-09-28 (financialexpress.com)
Dr. Reddy's Labs partners with IQVIA for improving customer interaction service in India - Healthcare News | The Financial Express
According to the company, OCE is IQVIA's CRM Application Suite that enables life sciences, clients, to digitally transform their sales and marketing operations.
Read more
(thehindubusinessline.com)
Dr Reddy’s to distribute Sanofi vaccines in India
Dr Reddy's Laboratories partners with Sanofi to distribute vaccine brands in India, aiming to expand access and reach.
Read more